EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives

Luca Filippi, Viviana Frantellizzi, Marko Magdi Abdou Sidrak, Joana Gorica, Stefano Scippa, Agostino Chiaravalloti, Orazio Schillaci, Oreste Bagni, Giuseppe De Vincentis

Onco · 2021

DOI: 10.3390/onco1020011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Onco, 2021. Verfasst von Luca Filippi und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma (NB) represents the most common extracranial tumor of childhood. Prognosis is quite variable, ranging from spontaneous regression to aggressive behavior with wide metastatization, high mortality, and limited therapeutic options. Radiotheranostics combines a radiopharmaceutical pair in a unique approach, suitable both for diagnosis and therapy. For many years, metaiodobenzylguanidine (MIBG), labeled with 123I for imaging or 131I for therapy, has represented the main theranostic agent in NB, since up to 90% of NB incorporates the aforementioned radiopharmaceutical. In recent years, novel theranostic agents hold promise in moving the field of NB radiotheranostics forward. In particular, SarTATE, consisting of octreotate targeting somatostatin receptors, has been applied with encouraging results, with 64Cu-SARTATE being used for disease detection and with 67Cu-SARTATE being used for therapy. Furthermore, recent evidence has highlighted the potential of targeted alpha therapy (TAT) for treating cancer by virtue of alpha particles’ high ionizing density and high probability of killing cells along their track. On this path, 211At-astatobenzylguanidine (MABG) has been developed as a potential agent for TAT and is actually under evaluation in preclinical NB models. In this review, we performed a web-based and desktop literature research concerning radiotheranostic approaches in NB, covering both the radiopharmaceuticals already implemented in clinical practice (i.e.,123/1311-MIBG) and those still in a preliminary or preclinical phase.

Zitieren

APA

Filippi, L., Frantellizzi, V., Sidrak, M. M. A., Gorica, J., Scippa, S., Chiaravalloti, A., Schillaci, O., Bagni, O., & Vincentis, G. D. (2021). Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives. Onco. https://doi.org/10.3390/onco1020011

Vancouver

Filippi L, Frantellizzi V, Sidrak MMA, Gorica J, Scippa S, Chiaravalloti A, et al. Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives. Onco. 2021. doi:10.3390/onco1020011

BibTeX
@article{Filippi2021,
  author = {Filippi, Luca and Frantellizzi, Viviana and Sidrak, Marko Magdi Abdou and Gorica, Joana and Scippa, Stefano and Chiaravalloti, Agostino and Schillaci, Orazio and Bagni, Oreste and Vincentis, Giuseppe De},
  title = {Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives},
  journal = {Onco},
  year = {2021},
  doi = {10.3390/onco1020011}
}
Kostenlos starten →